News
TRIB
2.825
-2.59%
-0.075
12 Health Care Stocks Moving In Tuesday's Intraday Session
Elutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. Trinity Biotech stock rose 20.61% and Akari Therapeutics shares moved upwards by 20.26%. The company's Q1 earnings report came out today.
Benzinga · 1d ago
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More
Trinity Biotech plc's share price has risen 34% in the last month. The company's price-to-sales ratio of 0.4x is lower than the rest of its industry. Trinity Biotech's forecasted revenue growth is higher than the broader medical equipment industry. However, the company's revenue growth has been in reverse gear over the last three years.
Simply Wall St · 1d ago
Weekly Report: what happened at TRIB last week (0603-0607)?
Weekly Report · 2d ago
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
Trinity Biotech plc plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida in June 2024. Trinity is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics. The company's senior management team will attend the event.
Barchart · 2d ago
Weekly Report: what happened at TRIB last week (0527-0531)?
Weekly Report · 06/03 09:27
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
Trinity Biotech plc is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions. The company has launched a continuous glucose monitoring microsite. The website will provide insight into the Company's vision for the development of its CGM technology and artificial intelligence.
Barchart · 06/03 03:00
Trinity Biotech Q1 Results Show Strong Growth
TipRanks · 05/28 14:04
Weekly Report: what happened at TRIB last week (0520-0524)?
Weekly Report · 05/27 09:28
TRIB Stock Earnings: Trinity Biotech Reported Results for Q1 2024
Trinity Biotech just reported results for the first quarter of 2024. The company reported earnings per share of -37 cents. Trinity Biotech reported revenue of $ million. The company has a market value of $1.2 billion. The stock was down 0.7% in the afternoon.
Investorplace · 05/23 16:53
Trinity Biotech GAAP EPADS of -$0.37, revenue of $14.7M
Trinity Biotech plc has a Q1 GAAP EPADS of -$ and revenue of $ The Group's cash balance increased from $ at the end of Q4, 2024 to $ in Q1, 2024. Trinity Biotech stock is down 1.7% in the last month.
Seeking Alpha · 05/23 12:08
TRINITY BIOTECH PLC - BASIC LOSS PER ADS FOR Q1, 2024 WAS $0.37
Reuters · 05/23 12:00
Notable earnings before Thursday's open
Seeking Alpha · 05/22 14:44
Trinity Biotech plc to Announce Q1 2024 Financial Results
Trinity Biotech plc will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30am ET. The company is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics. Trinity Biotech is a company in Ireland.
Barchart · 05/21 15:05
Weekly Report: what happened at TRIB last week (0513-0517)?
Weekly Report · 05/20 09:27
Earnings week ahead: NVIDIA, Target, Zoom Video, Snowflake and more
Seeking Alpha · 05/19 12:02
Trinity Biotech Announces Strategic Collaboration With Medical AI Co. PulseAI
NASDAQ · 05/16 18:20
Trinity Biotech Expects HIV Test Sales Surge
TipRanks · 05/16 17:57
TRINITY BIOTECH ANNOUNCES STRATEGIC COLLABORATION WITH MEDICAL ARTIFICIAL INTELLIGENCE COMPANY PULSEAI
Reuters · 05/16 13:18
Trinity Biotech Receives Increased Orders For TrinScreen HIV, Total Orders Received To Date For Supply In 2024 To ~$6M; Increased Its Expected 2024 Sales Revenue For TrinScreen HIV To Over $8M
Trinity Biotech plc says it has received additional orders for TrinScreen HIV. The company has increased its expected 2024 sales revenue for the rapid HIV tests to over $8 million. Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors.
Benzinga · 05/13 15:44
BRIEF-Trinity Biotech Receives Additional Orders For Trinscreen HIV
Trinity Biotech Receives Additional Orders For Trinscreen HIV. Company says it has increased its forecast for 2024 sales of HIV to over $8 million. Trinity Biotech says it received additional orders for trincreen HIV in the past week. The company is a supplier of trin screen HIV.
Reuters · 05/13 15:43
More
Webull provides a variety of real-time TRIB stock news. You can receive the latest news about Trinity Biotech Plc through multiple platforms. This information may help you make smarter investment decisions.
About TRIB
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.